Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study
drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis
and moderate organ dysfunction and will also evaluate measures of organ dysfunction,
mortality, and biological activity (secondary outcomes).